Visit us at booth #13 during the St.Gallen International Breast Cancer Conference 2023 to learn how the Prosigna Breast Cancer Assay was developed from the four PAM50 intrinsic subtypes and provides better prognostic accuracy and improves treatment decisions.

If you would like to book a meeting with the Veracyte’s Prosigna team, please submit a request and we will be in touch.